Co-founder and Chief Medical Officer, BioNTech
Appears in 1 story
Leading the company's oncology strategy
BioNTech's experimental mRNA cancer treatment failed its first major test on Tuesday. The drug, BNT113, combined with Merck's Keytruda, did not delay tumor progression in patients with HPV16-positive head and neck cancer, missing the trial's first dual primary endpoint.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
